These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37289635)

  • 41. Minimal stimulation protocol using letrozole versus microdose flare up GnRH agonist protocol in women with poor ovarian response undergoing ICSI.
    Mohsen IA; El Din RE
    Gynecol Endocrinol; 2013 Feb; 29(2):105-8. PubMed ID: 23134528
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
    Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
    J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cumulative Live Birth Rate and Cost-Effectiveness Analysis of Gonadotropin Releasing Hormone-Antagonist Protocol and Multiple Minimal Ovarian Stimulation in Poor Responders.
    Liu Y; Su R; Wu Y
    Front Endocrinol (Lausanne); 2020; 11():605939. PubMed ID: 33519714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Repeated GnRH agonist doses for luteal support: a proof of concept.
    Wiser A; Klement AH; Shavit T; Berkovitz A; Koren RR; Gonen O; Amichay K; Shulman A
    Reprod Biomed Online; 2019 Nov; 39(5):770-776. PubMed ID: 31628035
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.
    Kadoura S; Alhalabi M; Nattouf AH
    Sci Rep; 2022 Mar; 12(1):4456. PubMed ID: 35292717
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A drop in serum progesterone from oocyte pick-up +3 days to +5 days in fresh blastocyst transfer, using hCG-trigger and standard luteal support, is associated with lower ongoing pregnancy rates.
    Uyanik E; Mumusoglu S; Polat M; Yarali Ozbek I; Esteves SC; Humaidan P; Yarali H
    Hum Reprod; 2023 Feb; 38(2):225-236. PubMed ID: 36478179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle, but not the cumulative live birth rate in normal responders: a randomized controlled trial and molecular mechanism study.
    Xu B; Geerts D; Hu S; Yue J; Li Z; Zhu G; Jin L
    Hum Reprod; 2020 Jun; 35(6):1306-1318. PubMed ID: 32478400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of letrozole co-treatment during ovarian stimulation with gonadotrophins for IVF: a multicentre, randomized, double-blinded placebo-controlled trial.
    Bülow NS; Skouby SO; Warzecha AK; Udengaard H; Andersen CY; Holt MD; Grøndahl ML; Nyboe Andersen A; Sopa N; Mikkelsen ALE; Pinborg A; Macklon NS
    Hum Reprod; 2022 Jan; 37(2):309-321. PubMed ID: 34792133
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF/ICSI].
    Wu CX; Zhang T; Shu L; Huang J; Diao FY; Ding W; Gao Y; Wang W; Mao YD; Cui YG; Liu JY
    Zhonghua Fu Chan Ke Za Zhi; 2018 Mar; 53(3):160-166. PubMed ID: 29609229
    [No Abstract]   [Full Text] [Related]  

  • 50. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
    Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
    Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the cumulative live birth rates after 1 in vitro fertilization cycle in women using gonadotropin-releasing hormone antagonist protocol vs. progestin-primed ovarian stimulation: a propensity score-matched study.
    Chen H; Teng XM; Sun ZL; Yao D; Wang Z; Chen ZQ
    Fertil Steril; 2022 Oct; 118(4):701-712. PubMed ID: 35940929
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Follicular synchronization using transdermal estradiol patch and GnRH antagonists in the luteal phase; does it increase oocyte yield in poor responders to gonadotropin stimulation for in vitro fertilization (IVF)? A comparative study with microdose flare-up protocol.
    Ata B; Zeng X; Son WY; Holzer H; Tan SL
    Gynecol Endocrinol; 2011 Nov; 27(11):876-9. PubMed ID: 21495800
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
    Xiao ZN; Peng JL; Yang J; Xu WM
    Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Luteal-phase protocol in poor ovarian response: a comparative study with an antagonist protocol.
    Wu Y; Zhao FC; Sun Y; Liu PS
    J Int Med Res; 2017 Dec; 45(6):1731-1738. PubMed ID: 28661216
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determinants of the hCG Concentration in the Early Luteal Phase After Final Maturation of Follicles With Bolus Trigger of Recombinant hCG.
    Vuong LN; Pham TD; Ho VNA; Ho TM; Humaidan P; Andersen CY
    Front Endocrinol (Lausanne); 2020; 11():137. PubMed ID: 32265836
    [No Abstract]   [Full Text] [Related]  

  • 57. Fixed Gonadotropin-Releasing Hormone Antagonist Protocol
    Dong M; Sun L; Huang L; Wang F; Zhang X; Liu F
    Front Endocrinol (Lausanne); 2021; 12():690575. PubMed ID: 34867773
    [TBL] [Abstract][Full Text] [Related]  

  • 58. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
    Yılmaz N; Ceran MU; Ugurlu EN; Gülerman HC; Engin Ustun Y
    J Obstet Gynaecol; 2020 Aug; 40(6):837-842. PubMed ID: 31791167
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GnRHa flare and IVF pregnancy rates.
    Confino E; Zhang X; Kazer RR
    Int J Gynaecol Obstet; 2004 Apr; 85(1):36-9. PubMed ID: 15050465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.